Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multip...
Saved in:
| Published in: | Drug design, development and therapy Vol. 7; pp. 131 - 138 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New Zealand
Dove Medical Press Limited
01.01.2013
Taylor & Francis Ltd Dove Press Dove Medical Press |
| Subjects: | |
| ISSN: | 1177-8881, 1177-8881 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naïve patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe. |
|---|---|
| AbstractList | Alemtuzumab (previously known as Campath[R]) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-la) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naive patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-la, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE- MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe. Alemtuzumab (previously known as Campath[R]) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-la) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naive patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-la, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE- MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe. Keywords: alemtuzumab, Campath, efficacy, relapsing-remitting multiple sclerosis Alemtuzumab (previously known as Campath®) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing–remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naïve patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%–74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%–71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14–1.2 points, culminating in a net advantage with alemtuzumab of 0.41–0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2–8.66 versus 4.9–5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%–18% versus 5%–6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing–remitting multiple sclerosis in the United States and Europe. Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naïve patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe. Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naïve patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe.Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been reported. Two of these rater-blinded randomized studies assessed clinical and radiological outcomes in treatment-naïve patients; one explored patients who had relapsed despite first-line therapy. Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group. After alemtuzumab, the Expanded Disability Status Scale score improved by 0.14-1.2 points, culminating in a net advantage with alemtuzumab of 0.41-0.77 points over interferon in the CAMMS223 and CARE-MS2 trials (both P < 0.001). Radiological markers of new lesion formation and brain atrophy following alemtuzumab were significantly improved when compared to interferon in all studies. Adverse events were more common following alemtuzumab than interferon beta-1a (7.2-8.66 versus 4.9-5.7 events per person-year). While infusion reactions are the most common, autoimmunity is the most concerning; within Phase III studies, thyroid disorders (17%-18% versus 5%-6%) and immune thrombocytopenic purpura (1% versus 0%) were reported in patients taking alemtuzumab and interferon beta-1a, respectively. All patients responded to conventional therapy. One patient taking alemtuzumab in the Phase II study suffered a fatal intracranial hemorrhage following immune thrombocytopenic purpura, heralding assiduous monitoring of all patients thereafter. Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe. |
| Audience | Academic |
| Author | Coles, Alasdair Brown, William |
| Author_xml | – sequence: 1 givenname: William surname: Brown fullname: Brown, William – sequence: 2 givenname: Alasdair surname: Coles fullname: Coles, Alasdair |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23494602$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1rHCEUhoeS0ny0V70vA4USKLsddWbUXBSWbL8gUEr3XlznuGtwdKrOQvvr47BpshuiF8rxeY-Hc97z4sR5B0XxFlVzjGr6ablcrua_CW4ZfVGcIUTpjDGGTg7up8V5jLdV1ZIWV6-KU0xqXrcVPit-LSz0afw39nJ9VcLOdOAUlNqH0qRYDj6BS0ba0rgygJVDNG4zC9CblPKt7EebzGChjMpC8NHE18VLLW2EN_fnRbH6-mV1_X128_Pbj-vFzUw1CKWZ0tAqkIpotaYKV02DWSel4qBbzRUoxogmXYNkS3GTGcZVJ8las5pTKclF8XmfdhjXPXQqlxmkFUMwvQx_hZdGHL84sxUbvxOk4YS2JCeo9gk6v4MhQIxH4seo8r1AmFCeJZf3fwb_Z4SYRG-iAmulAz9GgQiirGactxl9_wS99WNwuSECT4szUuFHaiMtCOO0z6WqKalYEFq3vEb1RM2fofLu8hhUNoM2OX4k-HAg2IK0aRu9HZPxLh6D7w6b-NCA__7IwMc9oPJsYwD9gKBKTO4Tk_vE3n2ZRk9oZZKcfs0FG_us5g4iD94y |
| CitedBy_id | crossref_primary_10_1016_j_jaut_2016_08_005 crossref_primary_10_1007_s40265_014_0195_7 crossref_primary_10_1111_bcp_12285 crossref_primary_10_1517_14712598_2014_887676 crossref_primary_10_1007_s40120_018_0110_3 crossref_primary_10_1177_1352458519898113 crossref_primary_10_1186_s40893_016_0011_1 crossref_primary_10_1111_ene_12883 crossref_primary_10_1186_s12974_024_03263_9 crossref_primary_10_1517_14712598_2014_866084 crossref_primary_10_1007_s00415_019_09195_2 crossref_primary_10_1097_NAN_0000000000000127 crossref_primary_10_1111_cns_70225 crossref_primary_10_3109_1547691X_2015_1089343 crossref_primary_10_1007_s10930_024_10188_y crossref_primary_10_1007_s40263_018_0538_0 crossref_primary_10_1016_j_drudis_2013_12_002 crossref_primary_10_1177_1352458518754999 crossref_primary_10_1038_nrrheum_2013_168 crossref_primary_10_1002_brb3_518 crossref_primary_10_1016_j_vaccine_2014_06_068 crossref_primary_10_3390_ijms21175960 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2013 Dove Medical Press Limited 2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2013 Brown and Coles, publisher and licensee Dove Medical Press Ltd 2013 |
| Copyright_xml | – notice: COPYRIGHT 2013 Dove Medical Press Limited – notice: 2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2013 Brown and Coles, publisher and licensee Dove Medical Press Ltd 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QO 7RV 7XB 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH KB0 M2O MBDVC NAPCQ P64 PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.2147/DDDT.S32687 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Nursing & Allied Health Database ProQuest Central (purchase pre-March 2016) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep (ProQuest) Nursing & Allied Health Database (Alumni Edition) Research Library Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Biotechnology Research Abstracts ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database (ProQuest) url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1177-8881 |
| EndPage | 138 |
| ExternalDocumentID | PMC3593763 oai_dovepress_com_12379 A374694142 23494602 10_2147_DDDT_S32687 |
| Genre | Comparative Study Review Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0YH 29G 2WC 53G 5GY 5VS 7RV 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ACIWK ACPRK ADBBV ADRAZ AENEX AFFHD AFKRA AFRAH AIAGR ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD EMOBN F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW INH INR IPNFZ ITC KQ8 M2O M48 MK0 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PPXIY PQQKQ PROAC RIG RPM SV3 TDBHL TR2 UKHRP VDV ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QO 7XB 8FD 8FK FR3 MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 - ADACO BBAFP LI0 5PM |
| ID | FETCH-LOGICAL-c511t-cfe6ceac3fcb7c205528daac9ef6f9cec883f3d51a6725cb789cda3bf8497aa3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 25 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000315679300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1177-8881 |
| IngestDate | Tue Nov 04 02:04:39 EST 2025 Mon Jan 18 10:57:44 EST 2021 Sun Nov 09 12:24:40 EST 2025 Sat Jul 26 02:26:58 EDT 2025 Tue Nov 11 10:24:27 EST 2025 Tue Nov 04 17:24:03 EST 2025 Thu May 22 21:21:39 EDT 2025 Mon Jul 21 05:42:13 EDT 2025 Tue Nov 18 22:45:33 EST 2025 Sat Nov 29 03:14:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | relapsing–remitting multiple sclerosis alemtuzumab efficacy Campath |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c511t-cfe6ceac3fcb7c205528daac9ef6f9cec883f3d51a6725cb789cda3bf8497aa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2222298302?pq-origsite=%requestingapplication% |
| PMID | 23494602 |
| PQID | 2222298302 |
| PQPubID | 2046454 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3593763 dovepress_primary_oai_dovepress_com_12379 proquest_miscellaneous_1317848996 proquest_journals_2222298302 gale_infotracmisc_A374694142 gale_infotracacademiconefile_A374694142 gale_healthsolutions_A374694142 pubmed_primary_23494602 crossref_primary_10_2147_DDDT_S32687 crossref_citationtrail_10_2147_DDDT_S32687 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | Drug design, development and therapy |
| PublicationTitleAlternate | Drug Des Devel Ther |
| PublicationYear | 2013 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Press Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Press – name: Dove Medical Press |
| References | 17018123 - Transpl Int. 2006 Nov;19(11):885-92 23122652 - Lancet. 2012 Nov 24;380(9856):1819-28 21899662 - Eur J Neurol. 2012 Feb;19(2):307-11 22056965 - J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304 22364332 - Expert Rev Neurother. 2012 Mar;12(3):335-41 22411958 - Neurology. 2012 Mar 13;78(11):823-32 16044212 - J Neurol. 2006 Jan;253(1):98-108 19546505 - J Clin Invest. 2009 Jul;119(7):2052-61 8099991 - Lancet. 1993 Jun 26;341(8861):1620-2 9195505 - J Rheumatol. 1997 Jun;24(6):1031-6 9015484 - QJM. 1996 Dec;89(12):903-12 19763798 - J Clin Immunol. 2010 Jan;30(1):99-105 21442484 - Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Mar;14(3):199-201 18970977 - Lancet. 2008 Oct 25;372(9648):1502-17 8534657 - Br J Ophthalmol. 1995 Nov;79(11):1054-5 16510744 - N Engl J Med. 2006 Mar 2;354(9):899-910 18946064 - N Engl J Med. 2008 Oct 23;359(17):1786-801 9820297 - Lancet. 1998 Nov 7;352(9139):1498-504 20049473 - J Neurol. 2010 Jun;257(6):913-9 21397567 - Lancet Neurol. 2011 Apr;10(4):338-48 16510745 - N Engl J Med. 2006 Mar 2;354(9):911-23 18283404 - J Neurol. 2008 Feb;255(2):231-8 6685237 - Neurology. 1983 Nov;33(11):1444-52 20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401 22442431 - Neurology. 2012 Apr 3;78(14):1069-78 16231285 - Eur J Immunol. 2005 Nov;35(11):3332-42 7617182 - Neurology. 1995 Jul;45(7):1277-85 8602746 - Ann Neurol. 1996 Mar;39(3):285-94 23122650 - Lancet. 2012 Nov 24;380(9856):1829-39 7617181 - Neurology. 1995 Jul;45(7):1268-76 20089954 - N Engl J Med. 2010 Feb 4;362(5):402-15 8217808 - Br J Haematol. 1993 Jul;84(3):542-4 |
| References_xml | – reference: 18970977 - Lancet. 2008 Oct 25;372(9648):1502-17 – reference: 22442431 - Neurology. 2012 Apr 3;78(14):1069-78 – reference: 23122650 - Lancet. 2012 Nov 24;380(9856):1829-39 – reference: 7617181 - Neurology. 1995 Jul;45(7):1268-76 – reference: 16044212 - J Neurol. 2006 Jan;253(1):98-108 – reference: 8099991 - Lancet. 1993 Jun 26;341(8861):1620-2 – reference: 20089954 - N Engl J Med. 2010 Feb 4;362(5):402-15 – reference: 8217808 - Br J Haematol. 1993 Jul;84(3):542-4 – reference: 6685237 - Neurology. 1983 Nov;33(11):1444-52 – reference: 9820297 - Lancet. 1998 Nov 7;352(9139):1498-504 – reference: 7617182 - Neurology. 1995 Jul;45(7):1277-85 – reference: 16510745 - N Engl J Med. 2006 Mar 2;354(9):911-23 – reference: 8534657 - Br J Ophthalmol. 1995 Nov;79(11):1054-5 – reference: 22056965 - J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304 – reference: 22364332 - Expert Rev Neurother. 2012 Mar;12(3):335-41 – reference: 16510744 - N Engl J Med. 2006 Mar 2;354(9):899-910 – reference: 17018123 - Transpl Int. 2006 Nov;19(11):885-92 – reference: 21899662 - Eur J Neurol. 2012 Feb;19(2):307-11 – reference: 9195505 - J Rheumatol. 1997 Jun;24(6):1031-6 – reference: 8602746 - Ann Neurol. 1996 Mar;39(3):285-94 – reference: 20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401 – reference: 18946064 - N Engl J Med. 2008 Oct 23;359(17):1786-801 – reference: 19546505 - J Clin Invest. 2009 Jul;119(7):2052-61 – reference: 19763798 - J Clin Immunol. 2010 Jan;30(1):99-105 – reference: 20049473 - J Neurol. 2010 Jun;257(6):913-9 – reference: 23122652 - Lancet. 2012 Nov 24;380(9856):1819-28 – reference: 9015484 - QJM. 1996 Dec;89(12):903-12 – reference: 18283404 - J Neurol. 2008 Feb;255(2):231-8 – reference: 16231285 - Eur J Immunol. 2005 Nov;35(11):3332-42 – reference: 21442484 - Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Mar;14(3):199-201 – reference: 21397567 - Lancet Neurol. 2011 Apr;10(4):338-48 – reference: 22411958 - Neurology. 2012 Mar 13;78(11):823-32 |
| SSID | ssj0063620 |
| Score | 2.0883107 |
| SecondaryResourceType | review_article |
| Snippet | Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in... Alemtuzumab (previously known as Campath[R]) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in... Alemtuzumab (previously known as Campath®) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in... |
| SourceID | pubmedcentral dovepress proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 131 |
| SubjectTerms | Adjuvants, Immunologic - adverse effects Adjuvants, Immunologic - therapeutic use Alemtuzumab Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD - immunology Antigens, Neoplasm - immunology Atrophy Autoimmunity Brain Campath CD52 Antigen Clinical trials Drug therapy efficacy Glycoproteins - immunology Hemorrhage Humans Immunotherapy Interferon Interferon beta-1a Interferon-beta - adverse effects Interferon-beta - pharmacology Interferon-beta - therapeutic use Lymphocytes Lymphopenia Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - physiopathology Patients Pharmaceutical research Purpura relapsing-remitting multiple sclerosis Review Therapy Thrombocytopenic purpura Thyroid Treatment Outcome |
| Title | Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23494602 https://www.proquest.com/docview/2222298302 https://www.proquest.com/docview/1317848996 http://www.dovepress.com/getfile.php?fileID=15384 https://pubmed.ncbi.nlm.nih.gov/PMC3593763 |
| Volume | 7 |
| WOSCitedRecordID | wos000315679300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: M~E dateStart: 20070101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: AUTh Library subscriptions: ProQuest Central customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: BENPR dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database (ProQuest) customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: 7RV dateStart: 20070101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: PIMPY dateStart: 20070101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: M2O dateStart: 20070101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAWR databaseName: Taylor & Francis Journals (OA) customDbUrl: eissn: 1177-8881 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0063620 issn: 1177-8881 databaseCode: 0YH dateStart: 20090901 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwELdYh8Re-P8nMIqRpiHQwto4sR1eUKGbQGIl2ipUniLHcbRIa1qadNJ44jvwDfkk3CVp2gjEC3nIQ3xJ7Nz5zr7c_Y6QPeb0jFGG2TL2YYMCWx076rO-HTMuEqy56usyUfiTGI3kZOIHtcMtr8MqVzqxVNTxTKOP_NDBw0e0qrfzbzZWjcK_q3UJjS2yjUhlbodsvzsaBacrXcxBPfeqrDysx3M4HA7Hr89gxYIRdBt26EY8u6wCT__UzBumqR02uWGHjm_97whuk5v1CpQOKpG5Q66Z7C7ZDyoI66sDOl5nZOUHdJ8Ga3Drq3vkbHBhpsXy-3KqojfU1DVJKSx9aVrkdD4rMPwInp9mFPNk5uiL-PXj58JM0zLEmq5CGGkOr4dvk-b3yfj4aPz-g10XZrA1rM8KWyeGa9DYLNGR0E7P8xwZK6V9k_AEmKulZAmLvb7iwvGARvo6VixKpOsLpdgD0slmmXlEaKIiyXkc-xpx_Hii3L4fe8yNpMeNK6RFXq24FOoatBxrZ1yEsHlBlobI0rBiqUX2GuJ5hdXxd7KXDbsbOkTZXl8FtoVg0oVvkWcoDmGVlNpog3DAhIspwK5jkRclBeoD6JlWdVoDjA-RtVqUuy1KmMe63bwSm7DWI3m4lhmLPG-a8U6MjcvMbJmHMLWEdGHfzC3ysJLQZlgOog9xvFu0ZLc17nZLlp6XKOPM89H4PP53t56QHacsEIJOqV3SKRZL85Rc15dFmi-6ZEucfsHzRHbrqdktvR5wPnE-w7Xg40nw9TeIq0tt |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBov3C-BwYw0hoYW1sa52EgIVZRp00o1sQrtzXIcR0Ra09KkQ-WJ_8Dv4E_xSzgntzYC8bYH-lifpHbz-TvnOOdCyDZzOsYow2weCXBQwNWxwy7r2hHzgxh7rgpdJAoPguGQn52JkzXys86FwbDKmhMLoo4mGs_I9x38CKxW9Xb6xcauUfh2tW6hUcLi2Cy-gsuWvTnqw_N97jgH70fvDu2qq4CtwbjIbR0bXwPdsFiHgXY6nufwSCktTOzHMDPNOYtZ5HWVHzgeyHChI8XCmLsiUIrBba-Qq0DjXYwgCz5-qonfB13QKVMAsfnPfr_fH706BfMIw_VWlN5GNLkoo1z_VAMrerAdo7mi9A5u_md_1y1yo7Kuaa_cDrfJmknvkJ2Tsjz3Yo-Oltlm2R7doSfLwt2Lu-S0d27G-fzbfKzC19RU_VYpmPU0yTM6neQYWgX3T1KKOUBTPGf59f3HzIyTInyc1uGZNIOfh0eRZPfI6DLWe5-sp5PUPCQ0ViH3_SgSGmsU-rFyuyLymBtyzzduwC3ysgaF1FVBduwLci7BMUMESUSQLBFkke1GeFrWIfm72G6DrkYOK4gvvwWUSDBXAmGRLUSfLBNuG6aTPRa4mN7sOhZ5UUgg18HMtKpSNmB9WDWsJbnZkgSO0u3hGqWy4shMLiFqkWfNMF6JcX-pmcwzCbQRcJeDU26RB-WGaJblYGUlH68OWlulte72SJp8LiqoM0-gYn3072ltkY3D0YeBHBwNjx-T607RCAUP3zbJej6bmyfkmr7Ik2z2tOABSuQlb6TfttGl9g |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgoAL74eh0EUqRaCaJF7bu4uEUESIqFqFSM2ht5W9XgtLjRNipyic-A_8Gv4Ov4QZvxILxK0HcsyOnd14dh7rb74hZI85XWMCw2wRSUhQINWxwx7r2RHzeYw9V6UuCoWP-WgkTk_leIv8rGthEFZZ28TCUEczjWfkHQc_EtmqOnEFixgPhu_mX2zsIIVvWut2GqWKHJnVV0jfsreHA3jWzx1n-GHy_qNddRiwNQQaua1j42swPSzWIddO1_McEQWBlib2Y5ilFoLFLPJ6gc8dD2SE1FHAwli4kgcBg9teIpe5Cz4ZUYPOp9oJ-OAXumU5IDYC6gwGg8nrEwiVELq34QCvRbPzEvH6p0vY8IltvOaGAxze_I__ulvkRhV10365TW6TLZPeIfvjkrZ7dUAn6yq07IDu0_Ga0Ht1l5z0z8w0X35bToPwDTVVH1YK4T5N8ozOZzlCruD-SUqxNmiO5y-_vv9YmGlSwMppDdukGfw8PJYku0cmF7He-2Q7naXmIaFxEArfjyKpkbvQjwO3JyOPuaHwfONyYZFXtYIoXRG1Y7-QMwUJG2qTQm1SpTZZZK8Rnpf8JH8Xe9loWiOHzOLrb0FjFIQxXFpkFzVRlYW4jQVUfcZdLHt2HYu8KCTQBsLMdFCVcsD6kE2sJbnTkgTbpdvDtcaqynZmaq2uFnnWDOOViAdMzWyZKTAnXLgCknWLPCg3R7MsBxmXfLyat7ZNa93tkTT5XDCrM0-iw33072ntkquwf9Tx4ejoMbnuFP1R8Exuh2zni6V5Qq7o8zzJFk8Lk0CJuuB99BuwRK6T |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alemtuzumab%3A+evidence+for+its+potential+in+relapsing-remitting+multiple+sclerosis&rft.jtitle=Drug+design%2C+development+and+therapy&rft.au=Brown%2C+J.+William+L&rft.au=Coles%2C+Alasdair+J&rft.date=2013-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1177-8881&rft.eissn=1177-8881&rft.volume=7&rft.spage=131&rft_id=info:doi/10.2147%2FDDDT.S32687&rft.externalDocID=A374694142 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-8881&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-8881&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-8881&client=summon |